INTRODUCTION Interleukin-1 receptor associated kinase 4 (IRAK4) plays a central role in myddosome signaling via kinase and scaffolding functions, making it an attractive target for the treatment of TLR- and IL -1R-driven inflammatory diseases. IL-1 family cytokines, Th17 cells and TLRs, are central to the pathophysiology of several chronic inflammatory diseases. IRAK4 exhibits both kinase dependent and independent activities, making degradation a more attractive modality than kinase inhibition alone. Kymera has developed orally administered hetero- bifunctional molecules that selectively target IRAK4 for degradation and elimination by the ubiquitin proteasome pathway. These degraders have broad and potent activity in vitro against IL -6, TNF- a and other proinflammatory cytokines and chemo

Join for free to read